Research progress in the application of time in range: more than a percentage

作     者：Jintao Wan Jingyi Lu Cheng Li Xiaojing Ma Jian Zhou 

作者机构：Department of Endocrinology and MetabolismShanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai Clinical Center for DiabetesShanghai Key Clinical Center for Metabolic DiseaseShanghai Diabetes InstituteShanghai Key Laboratory of Diabetes MellitusShanghai 200233China. 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第5期

页      面：522-527页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：Program of Shanghai Academic/Technology Research Leader(No.22XD1402300) National Key R&D Program of China(No.2018YFC2001004) Shanghai"Rising Stars of Medical Talent"Youth Development Program-Outstanding Youth Medical Talents(No.SHWSRS_99) 

主　　题：Diabetes mellitus Time in range Continuous glucose monitoring 

摘      要：Glucose monitoring is an important part of medical care in diabetes mellitus,which not only helps assess glycemic control and treatment safety,but also assists with treatment adjustment.With the development of continuous glucose monitoring(CGM),the use of CGM has increased rapidly.With the wealth of glucose data produced by CGM,new metrics are greatly needed to optimally evaluate glucose status and guide the treatment.One of the parameters that CGM provides,time in range(TIR),has been recognized as a key metric by the international consensus.Before the adoption of TIR in clinical practice,several issues including the minimum length of CGM use,the setting of the target range,and individualized TIR goals are summarized.Additionally,we discussed the mounting evidence supporting the association between TIR and diabetes-related outcomes.As a novel glucose metric,it is of interest to compare TIR with other conventional glucose markers such as glycated hemoglobin A1c.It is anticipated that the use of TIR may provide further information on the quality of glucose control and lead to improved diabetes management.